15 Recruiting Recurrent B-Cell Non-Hodgkin Lymphoma Clinical Trials
Explore open interventional and observational research studies actively enrolling participants across the USA. Verify eligibility and contact site coordinators directly.
📍 Find Near Me by DistanceBrowse by Study Phase
Top Interventions for Recurrent B-Cell Non-Hodgkin Lymphoma
Related Conditions
Top Recruiting Recurrent B-Cell Non-Hodgkin Lymphoma Studies
Testing the Combination of Nivolumab and ASTX727 for Relapsed or Refractory B-Cell Lymphoma
📍 University of Alabama at Birmingham Cancer Center — Birmingham, Alabama
View Study & Checklist ➔Trial of ONC-PluReceptor NK Cells With Epcoritamab and Tafasitamab for Patients With Recurrent or Refractory B-cell Non-Hodgkin Lymphoma
📍 The University of Texas M. D. Anderson Cancer Center — Houston, Texas
View Study & Checklist ➔Epcoritamab and Lenalidomide in Treating Patients With Refractory or Relapsed Immunodeficiency-Related Large B-Cell Lymphoma
📍 Northwestern University — Chicago, Illinois
View Study & Checklist ➔A Phase I/II Study to Evaluate the Safety of Cellular Immunotherapy Using Autologous T Cells Engineered to Express a CD20-Specific Chimeric Antigen Receptor for Patients With Relapsed or Refractory B Cell Non-Hodgkin Lymphomas
📍 Fred Hutch/University of Washington Cancer Consortium — Seattle, Washington
View Study & Checklist ➔Testing the Safety of the Anti-cancer Drugs Tazemetostat and Belinostat in Patients With Lymphomas That Have Resisted Treatment
📍 University of California Davis Comprehensive Cancer Center — Sacramento, California
View Study & Checklist ➔A Cognitive Training Intervention for Improving Cognitive and Neurological Outcomes in Patients Undergoing Treatment for Relapsed or Refractory Multiple Myeloma or B-cell Non-Hodgkin Lymphoma
📍 Ohio State University Comprehensive Cancer Center — Columbus, Ohio
View Study & Checklist ➔CD19-Directed CAR-T Cell Therapy for the Treatment of Relapsed/Refractory B Cell Malignancies
📍 Mayo Clinic in Rochester — Rochester, Minnesota
View Study & Checklist ➔Alisertib, Bortezomib, and Rituximab in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma or B-cell Low Grade Non-Hodgkin Lymphoma
📍 Laura and Isaac Perlmutter Cancer Center at NYU Langone — New York, New York
View Study & Checklist ➔An Early Phase Study of Venetoclax, Lenalidomide, and Rituximab/Hyaluronidase in Slow-Growing Lymphomas That Have Come Back After Treatment or Have Not Responded to Treatment
📍 Sidney Kimmel Cancer Center at Thomas Jefferson University — Philadelphia, Pennsylvania
View Study & Checklist ➔